| Background and Objective: A number of hepatocellular carcinoma cells and even liver stem cell antigens have been identified in hepatic stem cell, among which several kinds of antigens are key molecules of signal channels that keeps the hepatocellular carcinoma to proliferate unlimitedly. Common antigens or cell-surface molecules are found between adult stem cells of various kinds and tumor cells. Therefore, vaccines made from hepatic stem cells could be vaccinated into the body of mice to activate their immune system to produce specific antibodies and effector T cell which recognize and kill hepatocellular carcinoma cells and even their stem cells, that can inhibit the forming and growth of stem cells, which cures hepatic carcinoma fundamentally. Our preliminary study has demonstrated the prevention and therapeutic effect of hepatic stem cell vaccine to transplanted hepatic carcinoma of mice. This study furtherly explores the immune regulation mechanism of hepatic-stem-cell vaccine has in prevention and treatment of mice hepatic carcinoma.Methods: 1. C57BL/6J mice of the age of 10-14 are randomly assigned into 3 groups(6 per group), with the name individually hepatic stem cell vaccine prevention group, 1.Hepa1-6 cell vaccine prevention group, and PBS control group, each group of mice are vaccinated once a week, totally 3 times, and the subcutaneous transplantable hepatoma is built within a week after the vaccination. ELISA is used to detect the anti-Ig G antibody titer of the peripheral blood of mice in prevention group and treatment group near the end of research, and by complement dependent CDC, the antibodies generated are detected if contains the anti-tumor potential, lymphocytes of mice spleen are separated and the killing toxicity of CTL to target cells is tested using LDH. FCM is applied to detect the ratio of Treg/CD4+T cells in the lymph tissue of mice spleen. This research focuses on the immune-regulation mechanism ofhepatic stem cells vaccine in preventing mice hepatic tumor.Results: in Group 1, in the vaccinated mice with liver cancer hepatic stem cells average tumor size is less than Hepa1-6 cells vaccine Group(P<0.05) and average weight of hepatic stem cells in the vaccine group tumors in mice(0.12 ± 0.06g) compared with Hepa1-6 cells vaccine Group(0.23 ± 0.05g) light, with significant differences(P<0.05). ELISA method for detection of hepatic stem cells in mouse peripheral blood Ig G antibodies the vaccine Group(67.19 ± 9.13ng/ml) than that of Hepa1-6 cells vaccine Group(49.67 ± 10.95ng/ml); by complement-dependent cytotoxicity assay of antibodies anti-tumor effect of hepatic stem cells in hepatocellular carcinoma mortality in the vaccine Group(43.86 ± 8.33%) than that of Hepa1-6 cells vaccine Group(32.91+3.23%), There was a significant difference(P<0.05). Hepatic stem cells in the vaccine group mice CTL killing rate is higher than Hepa1-6 cells to Hepa1-6 cells vaccine groups, the differences were statistically significant(P<0.05). Hepatic stem cells in mouse spleen lymphocytes in the vaccine Group share of Tregs in CD4+T cells(5.52 ± 0.05%) compared with Hepa1-6 cells vaccine Group(8.76 ± 0.41%), there were significant differences(P<0.05).2, in the treatment group, hepatic stem cells in mice subcutaneous vaccines the average volume of liver cancer is less than Hepa1-6 cells vaccine groups, average weight of liver stem cell tumor vaccine Group(0.13 ± 0.07g) compared with Hepa1-6 cells vaccine Group(0.24 ± 0.05g) light, with significant differences(P<0.05). Hepatic stem cells in the vaccine group amount of Ig G antibody in peripheral blood in mice(62.39 ± 10.09ng/ml) than that of Hepa1-6 cells vaccine Group(47.92 ± 12.10ng/ml), a statistically significant difference(P<0.05), complement-dependent cells of experimental detection of hepatic stem cells in hepatocellular carcinoma mortality in the vaccine Group(41.91 ± 9.45%) than that of Hepa1-6 cells vaccine Group(33.17 ± 4.88%) There was a significant difference(P<0.05). Hepatic stem cells in the vaccine group mice CTL killing rate is higher than Hepa1-6 cells to Hepa1-6 cells vaccine groups, the differences were statistically significant(P<0.05). Hepatic stem cells in mouse spleen lymphocytes in the vaccine Group share of Tregs in CD4+T cells(6.65 ± 1.13%) than Hepa1-6 cells vaccine Group(8.84 ± 0.45%), there were significantdifferences(P<0.05).Conclusions: 1, and liver stem cell vaccine has inhibit small rat skin xià liver cancer transplant tumor growth role; 2, and liver stem cell vaccine in prevention and treatment small rat liver cancer in the are can induced Dutch tumor small rat body produced special heterosexual antibody and effect t cell; 3, and Dutch tumor small rat body Tregs/CD4+T proportions and Dutch tumor small rat tumor load into are related, Tregs may inhibit or weakened small rat body immune cell anti-tumor role. |
PDF Full Text Request